A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Does study drug Mavacamten vs. placebo have benefit on exercise capacity in adults w/ symptomatic obstructive hypertrophic cardiomyopathy.
Sponsor: Myokardia, Inc.
Enrolling: Male and Female Patients
Study Length: 10 Months
Clinic Visits: 12
IRB Number: AAAR8152
U.S. Govt. ID: NCT03470545
Contact: Andrea Kim: 212-305-1368 / caccresearch@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effect of the investigational drug, Mavacamten, to a placebo (an inactive drug). This is being done to evaluate whether Mavacamten is safe in obstructive Hypertrophic Cardiomyopathy (HCM) patients and helps to improve symptoms or ability to exercise. Mavacamten is an investigational drug. This means that it has not been approved by the Food and Drug Administration (FDA) or any regulatory agency for routine clinical use, including the treatment of HCM.
This study is closed
Investigator
Mathew Maurer, MD
Do You Qualify?
Do you have Hypertrophic Obstructive Cardiomyopathy? Yes No
Are you at least 18 years old? Yes No
Are you able to perform treadmill exercise testing? Yes No
Are you currently taking disopyramide or ranolazine? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Andrea Kim
caccresearch@cumc.columbia.edu
212-305-1368
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE